A Nikkei report on November 14 about Chugai Pharmaceutical’s possible divestment of its off-patent drug business to solder resist maker Taiyo Holdings is not based on official announcements, the two companies said on the same day. “There was a media…
To read the full story
Related Article
- Chugai to Offload 13 Off-Patent Brands to Taiyo Holdings
November 15, 2017
BUSINESS
- Japan Market Hits Record 11.8 Trillion Yen in FY2025, Keytruda Keeps Title: IQVIA
May 22, 2026
- Kissei Drops Call to Halt New Tavneos Use after Blue Letter Action
May 22, 2026
- Servier’s Voranigo Seen as Potential Standard of Care for Glioma: Expert
May 22, 2026
- Ultragenyx’s LC-FAOD Therapy Dojolvi Now Available in Japan
May 22, 2026
- SanBio Debuts Akuugo Stem Cell Therapy for Traumatic Brain Injury
May 22, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





